VC round-up: 8 December-4 January
This article was originally published in Scrip
Executive Summary
There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
You may also be interested in...
Galera Raises $150m To Take Lead Drug From Phase III To NDA Submission
Galera garnered $70m in Series C venture capital and $80m through a royalty deal tied to GC4419 and a follow-up drug for the treatment of severe oral mucositis caused by radiation therapy with an initial focus on head and neck cancer patients.
Q3 Review: Editor’s Picks Of Scrip's Top Stories
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.